These results also remind us that the detection of TP53 mutations cannot be fit for all the people at risk of cancer, and gene mutation testing combined with HPV status is the best way to predict the risk of HNSC because of the low TP53 mutation frequency in HPV-positive patients. This evidence concerns the gene TP53 and cancer.